08.05.2023 | Correction
Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 3/2023
Einloggen, um Zugang zu erhalten